Home
Drugs
Cisplatin

Cisplatin

Drug

Drug Profile

Cisplatin is a platinum-based chemotherapy medicine used to treat many solid tumors including testicular, ovarian, cervical, bladder, head and neck, lung cancers, mesothelioma, brain tumors, and neuroblastoma. It is administered intravenously and is prescription-only. It is a foundational antineoplastic drug on essential medicines lists.

Drug Class: Platinum-based antineoplastic
Approval Status: Licensed for medical use in 1978-1979; prescription-only in the US
Mechanism of Action: Binds and crosslinks DNA, interfering with DNA replication and mitosis and triggering apoptosis when damage cannot be repaired

Brand Names

Platinol

Indications

\Testicular cancer\
\Ovarian cancer\
\Cervical cancer\
\Bladder cancer\
\Head and neck cancer\
\Esophageal cancer\
\Lung cancer\
Mesothelioma
\Brain tumors\
Neuroblastoma

Related News

FDA Approvals and Pipeline Expansion Drive Bladder Cancer Therapeutics Market Growth

Jun 23, 2026

The bladder cancer therapeutics market is expanding with recent FDA approvals including INLEXZO for NMIBC and a KEYTRUDA-Padvev combination for MIBC, while the NMIBC market reached approximately USD 3 billion in 2025 across seven major markets. Ferring reported record revenues exceeding €2.5 billion in 2025, driven by Adstiladrin as its second major growth driver. A robust pipeline of emerging therapies is expected to further transform the market through 2036.

Multiple Oncology Trials Report Positive Results at ASCO 2026 and in Journals

Jun 02, 2026

Multiple oncology trials present recent results, including cabozantinib-nivolumab activity in non-clear cell RCC, savolitinib efficacy in MET-amplified gastric cancer, and induction nivolumab feasibility in HPV-driven oropharyngeal cancer.

Neoadjuvant chemoimmunotherapy shows high pathological response in squamous lung cancer

May 05, 2026

Neoadjuvant chemoimmunotherapy showed a 51.5% pathological complete response rate in 127 patients with resectable squamous cell lung cancer. Grade 3-4 treatment-related adverse events occurred in 11.8% of patients.

10-Year Survival Similar With Chemoradiation or Surgery in Resectable Advanced NSCLC

Apr 09, 2026

Ten-year follow-up of the phase 3 ESPATUE trial found similar overall and progression-free survival with chemoradiotherapy boost or surgery in resectable advanced NSCLC after induction therapy.

Clinical Trial Advances in Cancer Immunotherapy and Targeted Therapies

Apr 02, 2026

Moderna and Merck advance a Phase 2 trial of mRNA cancer vaccine V940 with pembrolizumab and chemotherapy for metastatic squamous NSCLC. In biliary tract cancer, first-line treatment combines chemotherapy with immunotherapy, while targeted therapy resistance prompts liquid biopsy. ImmunityBio tests a chemotherapy-free NK-cell regimen in non-Hodgkin lymphoma.

Junshi Biosciences Reports 28% Revenue Growth in 2025; Absci Schedules Q4 Results

Mar 13, 2026

Junshi Biosciences reported total revenue of approximately RMB2,498 million in 2025, a 28% increase year-over-year, driven by toripalimab sales growth. Absci Corporation announced it will report fourth quarter and full year 2025 financial results on March 24, 2026.

Immunotherapy Fails to Improve Survival in Two Cancer Trials

Mar 13, 2026

Two recent clinical trials found that adding immunotherapy to standard chemoradiation did not improve survival for patients with limited-stage small-cell lung cancer or high-risk HPV-positive oropharyngeal cancer, though both studies revealed important insights about treatment delivery and radiation scheduling.

Precision Medicine Advances Target Rare and Pediatric Cancers with Personalized Therapies

Mar 12, 2026

Researchers are developing personalized treatment approaches for rare and pediatric cancers using genetic profiling, AI-driven dosing, and 3D-printed medications to improve outcomes while reducing long-term toxicity.

Pembrolizumab Combinations Show Survival Benefits in Bladder and Ovarian Cancers

Mar 12, 2026

Pembrolizumab-based regimens demonstrated significant survival improvements in two separate trials: KEYNOTE-B15 for muscle-invasive bladder cancer and KEYNOTE-B96 for platinum-resistant ovarian cancer, with FDA approval granted for the ovarian cancer indication.

Merck Presents Bladder and Kidney Cancer Data at 2026 ASCO GU Symposium

Mar 12, 2026

Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07613567	A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer	NOT_YET_RECRUITING	PHASE3
NCT07598318	Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations	NOT_YET_RECRUITING	PHASE2/PHASE3
NCT07583550	Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer	NOT_YET_RECRUITING	PHASE2
NCT07583511	Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study	RECRUITING	PHASE2
NCT07579195	Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07566156	Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )	RECRUITING	PHASE3
NCT07559929	A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07554456	A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)	NOT_YET_RECRUITING	PHASE2/PHASE3
NCT07540390	GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.	NOT_YET_RECRUITING	PHASE3
NCT07531979	Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2	NOT_YET_RECRUITING	PHASE2